MOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aesthetics
Why now
Thesis: Private China biotech funding, no public-market read-through
Catalyst to watch: IPO or partnership disclosure
Main risk: Private deal, no tradable instrument affected
Why it matters
Private financing for a Chinese regenerative-aesthetics biotech signals continued consumer-health VC appetite but the company is not publicly traded.
Details
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an...
Related assets & topics
ConsumerChinaHealthcareSources
- prnewswire · 2026-09-28 09:42 UTC